| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/26/2003 | EP1284977A1 Thienodibenzoazulene compounds as tumor necrosis factor inhibitors |
| 02/26/2003 | EP1284974A2 Triazolyl tropane derivatives as ccr5 modulators |
| 02/26/2003 | EP1284963A1 Novel calcium receptor active molecules and method for preparing same |
| 02/26/2003 | EP1284959A1 Compounds for modulating the rage receptor |
| 02/26/2003 | EP1284958A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoidane derivatives |
| 02/26/2003 | EP1284753A2 Combination of growth hormone secretagogues and antidepressants |
| 02/26/2003 | EP1284739A1 Composition and method for intervening neuronal death using sulfasalazine |
| 02/26/2003 | EP1284736A2 Opioid antagonist compositions and dosage forms |
| 02/26/2003 | EP1284735A1 Apomorphine derivatives and methods for their use |
| 02/26/2003 | EP1284734A1 Protein kinase inhibitors |
| 02/26/2003 | EP1284731A1 Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders |
| 02/26/2003 | EP1284730A1 Aralkyl ester soft drugs |
| 02/26/2003 | EP1284729A1 A(beta)42 lowering agents |
| 02/26/2003 | EP1284727A1 Intracorporeal medicaments for photodynamic treatment of disease |
| 02/26/2003 | EP1284724A1 Method of preparing alkylated salicylamides via a dicarboxylate intermediate |
| 02/26/2003 | EP1284721A2 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes |
| 02/26/2003 | EP1284720A2 Method of treating hepatitis delta viral infection |
| 02/26/2003 | EP1237563A4 Nutritional composition, methods of producing said composition and methods of using said composition |
| 02/26/2003 | EP1212453A4 Method to identify gene function using small molecule probes |
| 02/26/2003 | EP1100797B1 Heterocyclic compounds as inhibitors of rotamase enzymes |
| 02/26/2003 | EP1052998A4 Compositions and methods for modulating cytokine release in response to genotoxic agents |
| 02/26/2003 | EP1042297B1 Carboxyl acid substituted heterocycles as metalloproteinase inhibitors |
| 02/26/2003 | EP1032386B1 Use of oxazolidinone derivatives for treating arthritis |
| 02/26/2003 | EP1028746B1 Method for producing igf-i sustained-release formulations |
| 02/26/2003 | EP1011726B1 Fused imidazole derivatives for improving oral bioavailability of pharmaceutical agents |
| 02/26/2003 | EP0934304B1 2-pyrimidineamine derivatives and processes for their preparation |
| 02/26/2003 | EP0929571B1 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators |
| 02/26/2003 | EP0920431B1 Thienopyrimidines |
| 02/26/2003 | EP0876348B1 Salts of quinoline derivatives as nk3 antagonists |
| 02/26/2003 | EP0822986B1 Antagonists of human interleukin-6 that are totally incapable of binding gp 130, and their use in the preparation of pharmaceutical compounds |
| 02/26/2003 | EP0770137B1 Improvements in production of proteins in host cells |
| 02/26/2003 | EP0759943B1 Monoclonal antibody specific for vascular endothelial cell antigen endoglyx-1, the antigen itself, and uses thereof |
| 02/26/2003 | EP0708763B1 Process for making hiv protease inhibitors |
| 02/26/2003 | EP0674621B1 Enantiomers of carbazole derivatives as 5-ht1-like agonists |
| 02/26/2003 | EP0655914B1 Use of Histamine-2 agonists for treatment of sexual dysfunction |
| 02/26/2003 | CN1399644A Novel human G-Protein coupled receptor |
| 02/26/2003 | CN1399638A Indoloazepines as vasopressin receptor antagonists |
| 02/26/2003 | CN1399636A Adenosine receptor antagonists and methods of making and using the same |
| 02/26/2003 | CN1399635A Piperazing derivatives as 5-HT1B antagonists |
| 02/26/2003 | CN1399634A Hydroxyalkanoyl aminolactams and related structure as inhibitors of A beta protein production |
| 02/26/2003 | CN1399633A 嘧啶衍生物 Pyrimidine derivatives |
| 02/26/2003 | CN1399622A Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| 02/26/2003 | CN1399573A Use of phthalazine derivatives |
| 02/26/2003 | CN1399548A Composition for treatment of external secretion disorders |
| 02/26/2003 | CN1399516A Novel composition |
| 02/26/2003 | CN1398966A Acidophilic thermostable mycose-base synthetase and its prepn and use |
| 02/26/2003 | CN1398639A Application of TIMP-4 gene in preparing medicine for treating cardiac vascular disease and repairing scar clinically |
| 02/26/2003 | CN1398635A Piracetam medicine composition with function of promoting thinking and memory and its prepn |
| 02/26/2003 | CN1398634A Kidney failure treating medicine |
| 02/26/2003 | CN1398607A Medicine for delaying senility and its prepn |
| 02/26/2003 | CN1102144C Noval pyrimidine derivatives and prepn. processes thereof |
| 02/26/2003 | CN1102049C Tonic compound deer fetus ointment and its preparation method |
| 02/26/2003 | CA2419744A1 A novel crystal of n-hydroxy-2(s)-methyl-5-ethoxymethoxy-4(s)-¬n-(4-phenoxyphenylcarbonyl)amino|pentanamide and a method for the preparation thereof and a pharmaceutical agent comprising the same as active ingredient |
| 02/25/2003 | WO2002018278A1 Method and apparatus for preparing aqueous dispersion of ultra-fine active carbon particles |
| 02/25/2003 | US6525215 HIV protease inhibitors |
| 02/25/2003 | US6525206 Compounds with high monoamine transporter affinity |
| 02/25/2003 | US6525202 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 02/25/2003 | US6525196 5HT1 antagonists for antidepressant therapy |
| 02/25/2003 | US6525193 Aminoaryl oxazolidinone N-oxides |
| 02/25/2003 | US6525184 Self-regulated apoptosis of inflammatory cells |
| 02/25/2003 | US6525102 Increasing storage stability of interleukin-2 by incorporating free base form arginine and succinic acid |
| 02/25/2003 | US6525077 Cyanoguanidine prodrugs |
| 02/25/2003 | US6525072 Prevention and treatment of cellular disorders such as cancer |
| 02/25/2003 | US6525070 Bipiperidine derivatives as modulators of CCR3 activity and as H1 antagonists |
| 02/25/2003 | US6525068 Hydronaphtalene compounds, prepared by a rhodium catalyzed ring opening reaction in the presence of phosphine ligand |
| 02/25/2003 | US6525059 Substituted pyrazoles as p38 kinase inhibitors |
| 02/25/2003 | US6525055 Allergic and inflammatory pathologies such as, for example, emphysema, chronic bronchitis, asthma and allergic rhinitis. |
| 02/25/2003 | US6525049 Pyrroloquinolones as antiviral agents |
| 02/25/2003 | US6525048 Aminomethylphenoxymethyl/benzisoxazole substituted azabicyclic compounds; depression, generalized anxiety disorder, obesity, migraine; 2-(5-Fluoro-benzo(d)isoxazol-3-y)-7-(3-morpholin-4-ylmethylphenoxymethyl) -octahydro-pyrido(1,2-a)pyrazine; |
| 02/25/2003 | US6525047 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair |
| 02/25/2003 | US6525041 Low molecular weight mimics of superoxide dismutase; inflammatory disorders, ischemic/reperfusion injury, stroke, atherosclerosis, and all other conditions of oxidant- induced tissue damage or injury |
| 02/25/2003 | US6525040 4,4-dimethyl-thieno-(3,2-e)-isoselenazine; antioxidants and cytoprotecting |
| 02/25/2003 | US6525036 Compounds and compositions as protease inhibitors |
| 02/25/2003 | US6525025 Controlling apoptosis; cardiovascular disorders; central nervous system disorders |
| 02/25/2003 | US6525019 Use of melanin for inhibition of angiogenesis and macular degeneration |
| 02/25/2003 | US6524855 Methods for inducing the differentiation of monocytes into functional dendritic cells |
| 02/25/2003 | US6524840 Polynucleotides, host cell expression systems, the encoded proteins, polypeptides and peptides |
| 02/25/2003 | US6524834 Protein capable of hydrolyzing organophosphorous acetylcholinesterase inhibitors for use as poison antedote |
| 02/25/2003 | US6524821 Anti-apoptotic compositions comprising the R1 subunit of herpes simplex virus ribonucleotide reductase or its N-terminal portion; and uses thereof |
| 02/25/2003 | US6524813 Novel polynucleotides and polypeptides of the spo0J family derived from Staphylococcus |
| 02/25/2003 | US6524799 DNA encoding sparc-related proteins |
| 02/25/2003 | US6524607 Nontoxic, nonglucocorticoid, biocompatible, biodegradable, controlled release material |
| 02/25/2003 | US6524593 N-acetyl aldosamines and related N-acetyl compounds, and their topical use |
| 02/25/2003 | US6524583 Inhibit angiogenesis and induce tumor regression, and have improved safety due to their specificity |
| 02/25/2003 | US6524556 Tricyclic compound dispersed in liquefied hydrofluoroalkane propellant; medium-chain fatty acid triglyceride as dispersant |
| 02/25/2003 | US6524347 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| 02/25/2003 | CA2420572A1 Method and apparatus for preparing aqueous dispersion of ultra-fine active carbon particles |
| 02/25/2003 | CA2032059C Wound treatment employing biologically active peptides |
| 02/21/2003 | WO2002024660A1 Imidazole derivatives or their salts |
| 02/21/2003 | WO2002020462A1 Benzoic acid derivatives and drugs containing the same as the active ingredient |
| 02/21/2003 | WO2002016354A1 Chromenone derivatives and their use for treating diseases in conjunction with 5-hta1 receptors and/or dopamine d2 receptors |
| 02/21/2003 | WO2002016328A1 Biphenyl derivatives and the use thereof as integrin inhibitors |
| 02/21/2003 | WO2002016323A1 Biphenyl derivatives and the use thereof as integrin inhibitors |
| 02/21/2003 | CA2420945A1 Imidazole derivatives or their salts |
| 02/21/2003 | CA2420208A1 Biphenyl derivatives and their use as integrin inhibitors |
| 02/21/2003 | CA2420206A1 Chromenone derivatives and the use thereof for the treatment of diseases in connection with 5-hta1 receptors and/or dopamine d2 receptors |
| 02/21/2003 | CA2420205A1 Biphenyl derivatives and the use thereof as integrin inhibitors |
| 02/21/2003 | CA2419722A1 Benzoic acid derivatives and drugs containing the same as the active ingredient |
| 02/21/2003 | CA2398766A1 Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction |
| 02/20/2003 | WO2003014702A2 Uses of mammalian cytokine; related reagents |